Lycia Therapeutics, Inc.
Filed Oct 5, 2026.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Oct 5, 2026
Contents
CAPITALIZATION
The following table sets forth our cash, cash equivalents and marketable securities and capitalization as of June 30, 2026:
non an actual basis;
non a pro forma basis, giving effect to (i) the automatic conversion of all outstanding shares of our convertible preferred stock as of June 30, 2026 into an aggregate of shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity in connection with the completion of this offering, and (ii) the filing and effectiveness of our restated certificate of incorporation upon the completion of this offering; and
non a pro forma as adjusted basis giving effect to (i) the pro forma adjustments described above, and (ii) the issuance and sale of shares of our common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
The pro forma and pro forma as adjusted information set forth below is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing.
You should read this table together with the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes, each included elsewhere in this prospectus.
| AS OF JUNE 30, 2026 | ||||
|---|---|---|---|---|
| ACTUAL · PRO FORMA · PRO FORMA AS ADJUSTED(1) | ||||
| (in thousands, except share and per share amounts) | ||||
| Cash, cash equivalents and marketable securities | $148,091 | $ | $ | |
| Convertible preferred stock, par value $0.0001 per share; 153,933,467 shares authorized, issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted | $277,056 | $— | $— | |
| Stockholders’ deficit: | ||||
| Preferred stock, par value $0.0001 per share; no shares authorized, issued and outstanding, actual; 10,000,000 shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted | — | — | — | |
| Common stock, par value $0.0001 per share; 210,270,000 shares authorized, 14,667,833 shares issued and 14,650,145 shares outstanding, actual; 500,000,000 shares authorized, shares issued and outstanding, pro forma; and 500,000,000 shares authorized, shares issued and outstanding, pro forma as adjusted | 1 | |||
| Additional paid-in capital | 4,711 | |||
| Accumulated other comprehensive loss | (97) | |||
| Accumulated deficit | (136,756) | |||
| Total stockholders’ (deficit) equity | (132,141) | |||
| Total capitalization | $144,915 | $ | $ | |
(1)Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of our pro forma as adjusted cash, cash equivalents and marketable securities, additional paid-in capital, total stockholders’ equity and total capitalization by approximately $ million, assuming that the number of shares offered, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0 million shares in the number of shares of our common stock offered in this offering would increase or decrease, as applicable, each of our pro forma as adjusted cash, cash equivalents and marketable securities, additional paid-in capital, total stockholders’ equity and total capitalization by approximately $ million, assuming the assumed initial public offering price remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted cash, cash equivalents and marketable securities, additional paid-in capital, total stockholders’ (deficit) equity, total capitalization, and shares of common stock outstanding as of June 30, 2026 would be $ million, $ million, $ million, $ million, and shares, respectively.
The number of shares of our common stock to be outstanding after this offering on a pro forma and pro forma as adjusted basis set forth in the table above is based on (i) shares of our common stock outstanding as of June 30, 2026, including shares of unvested restricted stock subject to repurchase and (ii) the automatic conversion of all shares of our outstanding convertible preferred stock as of June 30, 2026 into an aggregate of shares of our common stock in connection with the completion of this offering, and excludes:
n shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2026 under our 2020 Plan, with a weighted-average exercise price of $ per share;
n shares of our common stock reserved for future issuance under our 2026 Plan, which will become effective in connection with this offering; and
n shares of our common stock to be reserved for future issuance under our ESPP, which will become effective in connection with this offering.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.